You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Breast Cancer (BRCA)1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer BRCA1 Carriers: a Pilot Study

Withdrawn
  • BRCA1 Mutation
  • +2 more
  • Mifepristone 200 MG
  • Prophylactic mastectomy
  • Carmel, Indiana
  • +1 more
Dec 13, 2022

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)

Active, not recruiting
  • Breast Cancer
  • +3 more
  • Boston, Massachusetts
  • +2 more
Dec 21, 2022

Breast Cancer, Genetic Predisposition Trial in Rome, Varese (Genetic predisposition to breast cancer)

Recruiting
  • Breast Cancer
  • Genetic Predisposition
  • Genetic predisposition to breast cancer
  • Rome, Italy
  • +1 more
May 4, 2023

BRCA and NACT in TNBC Patients

Completed
  • Triple-Negative Breast Cancer
  • BRCA1/2 genetic testing
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023

Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • Dnipro, Ukraine
  • +1 more
Jun 17, 2023

Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)

Not yet recruiting
  • Triple Negative Breast Neoplasms
  • +7 more
  • (no location specified)
Aug 1, 2022

Breast Cancer After Ovarian Cancer During and/or After Therapy:

Recruiting
  • BRCA-Associated Breast Carcinoma
  • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 9, 2023

Ultra-rapid BRCA1/2 Status Screening Test in Theranostic

Not yet recruiting
  • Breast Cancer
  • Questionnaires
  • Communication of the results of the BRCA1/2 ultra rapid test
  • (no location specified)
Oct 26, 2023

Endocrine Disruptors and Life STILe in Breast Cancer Development

Recruiting
  • Breast Cancer
  • +5 more
    • Roma, Italy
      Alessandra Fabi
    Feb 25, 2023

    Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)

    Recruiting
    • Stage I Breast Cancer
    • +7 more
    • Baltimore, Maryland
    • +6 more
    Nov 11, 2022

    Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

    Active, not recruiting
    • Advanced Breast Cancer
    • +2 more
    • Talazoparib Tosylate
    • Stanford, California
      Stanford University Hospitals and Clinics
    Nov 16, 2022

    Breast Cancer Trial in Tucson, Albuquerque (Pegylated liposomal doxorubicin)

    Completed
    • Breast Cancer
    • Pegylated liposomal doxorubicin
    • Tucson, Arizona
    • +1 more
    Jan 9, 2023

    BRCA1 Hereditary Breast and Ovarian Cancer Syndrome Trial in Barretos (Doxorubicin, Carboplatin, Paclitaxel)

    Completed
    • BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
    • Barretos, SP, Brazil
      Barretos Cancer Hospital
    Dec 25, 2022

    Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2

    Recruiting
    • Hereditary Breast and Ovarian Cancer
      • Barcelona, Spain
        Hospital de la Santa Creu i Sant Pau
      Jun 3, 2022

      l, Laboratory and Epidemiologic Characterization of Individuals

      Completed
      • Familial Ovarian Cancer
      • +3 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Dec 31, 2022

        Searching for Novel Germline Mutations in Lobular Breast Cancer

        Recruiting
        • Lobular Breast Carcinoma
        • +3 more
        • Illumina panel
        • Milan, Italy
          European Institute of Oncology
        Sep 12, 2022

        Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

        Recruiting
        • Pancreatic Adenocarcinoma Metastatic
        • +14 more
        • Boston, Massachusetts
        • +1 more
        Dec 6, 2022

        Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by

        Completed
        • Breast Cancer
        • Blood test
        • Questionnaire
        • New York, New York
          Memorial Sloan Kettering Cancer Center
        Dec 27, 2021

        InheriteD brEast caNcer iTalian regIsTrY A

        Recruiting
        • Breast Cancer
          • Aviano, Pordenone, Italy
          • +11 more
          Apr 26, 2023

          Breast & Ovarian Cancer Risk Detection

          Recruiting
          • Adnexal Mass
          • +3 more
          • OVA360
          • Austin, Texas
            Silvana Franco
          Jul 20, 2022

          Hereditary Breast and Ovarian Cancer Trial in Cologne, Kiel, Munich (Structured exercise training plus mediterranean diet)

          Active, not recruiting
          • Hereditary Breast and Ovarian Cancer
          • Structured exercise training plus mediterranean diet
          • Cologne, Germany
          • +2 more
          Oct 25, 2022

          Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 Trial in Houston

          Recruiting
          • Advanced Breast Carcinoma
          • +14 more
          • Houston, Texas
            M D Anderson Cancer Center
          Mar 31, 2022

          Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ Trial in Houston (Behavioral,

          Active, not recruiting
          • Deleterious BRCA1 Gene Mutation
          • +5 more
          • Behavioral, Psychological or Informational Intervention
          • Questionnaire Administration
          • Houston, Texas
            M D Anderson Cancer Center
          Sep 22, 2022

          TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (olaparib, Durvalumab)

          Not yet recruiting
          • TNBC - Triple-Negative Breast Cancer
          • +2 more
          • (no location specified)
          Jan 12, 2022